Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Estin, Charles D.; Stevenson, U S; Plowman, Gregory D.; Hu, Shiu‐Lok; Sridhar, P.; Hellström, Ingegerd; Brown, Joseph P.; Hellström, Karl Erik

doi:10.1073/pnas.85.4.1052

Cited by 79 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42,44,46,57 -59 In some of those studies, costimulatory molecules or cytokines were used to enhance vaccine effects. 44,45,59,64 These studies have suggested a role for antibodies, 36 -41,43,47,48,51 -53,60,63,64 CTL, 36 -48 and delayed-type hypersensitive T cells, 36,37,46,53 although the role of these factors was not directly demonstrated by in vivo cell depletion or adoptive cell transfer. The mouse models targeting human carcinoembryonic Ag (CEA ) and MUC-1 with VV vaccines, 36,39 -41,43,45 -48,52,63 similar to the human GA733 model used in the present study, include Ags that are expressed by tumors and by normal tissues.…”

Section: Cancer Gene Therapymentioning

confidence: 99%

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice

Žaloudík

Jacob

et al. 2002

Cancer Gene Ther

View full text Add to dashboard Cite

The human colorectal carcinoma ( CRC ) -associated GA733 antigen ( Ag ), also named CO17 -1A / EpCAM / KSA / KS1 -4, has been a useful target in passive immunotherapy of CRC patients with monoclonal antibody ( mAb ) and in active immunotherapy with antiidiotypic antibodies or with recombinant protein. These approaches have targeted single epitopes ( monoclonal anti -GA733 antibodies and anti -idiotypic antibodies ) or extracellular domain epitopes ( recombinant protein ), primarily by B cells. To determine whether a reagent that induces immunity to a larger number of both B -and T -cell epitopes might represent a superior vaccine, we analyzed the capacity of full -length GA733 Ag expressing multiple potentially immunogenic epitopes and encoded by recombinant vaccinia virus ( VV GA733 -2 ) to induce humoral, cellular, and / or protective immunity in mice. VV GA733 -2 induced Ag -specific antibodies that reacted predominantly to unknown epitopes on the Ag and lysed Ag -positive CRC targets in conjunction with murine peritoneal macrophages as effector cells. Immunized mice developed Ag -specific, proliferative and delayed -type hypersensitive lymphocytes. VV GA733 -2 inhibited growth of ras -transformed syngeneic tumor cells expressing the human GA733 Ag in mice. These results suggest the potential of VV GA733 -2 as a candidate vaccine for patients with CRC, possibly in combination with recombinant GA733 -2 -expressing adenovirus, which has been shown to induce cytolytic antibodies and T cells as well as tumor protective effects in mice. The combined vaccine approach may be superior to the use of either vaccine alone in patients who are pre -immune to both viruses.

show abstract

Section: Cancer Gene Therapymentioning

confidence: 99%

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice

Žaloudík

Jacob

et al. 2002

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…The ability of poxviruses to induce strong CTL responses has led to consideration of their use as cancer vaccines. Recombinant vaccinia viruses that express viral antigens (101,112) or cellular tumor-associated antigens (113)(114)(115)(116) have provided prophylactic and therapeutic effects against experimental tumors. Cytokines (IL-2 and IL-12) and/or costimulatory molecules (B7-1 and B7-2) may enhance the immune effects in model systems (117,118).…”

mentioning

confidence: 99%

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

Moss

1996

Proc. Natl. Acad. Sci. U.S.A.

475

256

View full text Add to dashboard Cite

Vaccinia virus, no longer required for immunization against smallpox, now serves as a unique vector for expressing genes within the cytoplasm of mammalian cells. As a research tool, recombinant vaccinia viruses are used to synthesize and analyze the structure-function relationships of proteins, determine the targets of humoral and cell-mediated immunity, and investigate the types of immune response needed for protection against specific infectious diseases and cancer. The vaccine potential of recombinant vaccinia virus has been realized in the form of an effective oral wild-life rabies vaccine, although no product for humans has been licensed. A genetically altered vaccinia virus that is unable to replicate in mammalian cells and produces diminished cytopathic effects retains the capacity for high-level gene expression and immunogenicity while promising exceptional safety for laboratory workers and potential vaccine recipients.

show abstract

“…Despite the expression of trace amounts of cross-reactive melanotransferrin in normal tissues of primates, no adverse effects or normal tissue damage could be observed after eliciting the immune response against melanotransferrin (53). This suggests that vaccination with melanotransferrin (668-683) against melanotransferrin-expressing tumors may also be safely applicable in man.…”

Section: Discussionmentioning

confidence: 78%

“…Early studies using recombinant vaccinia virus vaccines against melanotransferrin in mice and Macaca fascicularis monkeys have shown that cell-mediated and humoral immune responses could be induced against melanotransferrin-expressing xenografts and transfected syngeneic tumor cells resulting in in vivo rejection of tumor cells (53,54). Despite the expression of trace amounts of cross-reactive melanotransferrin in normal tissues of primates, no adverse effects or normal tissue damage could be observed after eliciting the immune response against melanotransferrin (53).…”

Section: Discussionmentioning

confidence: 99%

A Novel Strategy for the Discovery of MHC Class II–Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope

et al. 2005

View full text Add to dashboard Cite

CD4+ helper T cells play a critical role in orchestrating host immune responses, including antitumor immunity. The limited availability of MHC class II-associated tumor antigens is still viewed as a major obstacle in the use of CD4 + T cells in cancer vaccines. Here, we describe a novel approach for the identification of MHC class II tumor-associated antigens (TAAs). By combining two-dimensional liquid chromatography and nanoelectrospray ionization tandem mass spectrometry, we developed a highly sensitive method for the detection of human leukocyte antigen (HLA)-DR-associated peptides of dendritic cells upon exposure to necrotic tumor cells. This approach led to the identification of a novel MHC class II-restricted TAA epitope derived from melanotransferrin. The epitope stimulated T cells derived from melanoma patients and healthy individuals and displayed promiscuity in HLA-DR restriction. Moreover, the same peptide was also presented by MHC class II-positive melanoma cells. This strategy may contribute to increase the number of tumor epitopes presented by MHC class II molecules and may support the development of more efficacious vaccines against cancer. (Cancer Res 2005; 65(21): 10068-78)

show abstract

Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy.

Cited by 79 publications

References 30 publications

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice

Inhibition of tumor growth by recombinant vaccinia virus expressing GA733/CO17-1A/EpCAM/KSA/KS1-4 antigen in mice

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.

A Novel Strategy for the Discovery of MHC Class II–Restricted Tumor Antigens: Identification of a Melanotransferrin Helper T-Cell Epitope

Contact Info

Product

Resources

About